Compare AbCellera Biologics Inc (ABCL) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Oxford Lane Capital Corp — how do they compare? AbCellera Biologics Inc trades at $9.8 (market cap $2.99B), while Oxford Lane Capital Corp trades at $9.46 (market cap $909.61M). The key difference: AbCellera Biologics Inc is far larger — about 3.3× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 25.76% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | OXLC | |
|---|---|---|
Market Cap | $2.99B | $909.61M |
Sector | Health | Financials |
52-Week High | $9.76 | $18.75 |
52-Week Low | $2.78 | $8.15 |
Enterprise Value | $2.58B | — |
Dividend Yield | — | 25.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
OXLC trades at $9.43, up 1.73% today, with a bullish technical signal from moving averages but mixed oscillators. The stock shows a low P/B of 0.88 but high P/S of 92.8, with recent earnings misses and a volatile net income margin of 100.85% in 2026. Dividends of $0.20 monthly are ongoing, while news highlights NAV discounts and sustainability concerns.
Outlook is cautious due to earnings volatility and high yield risks; opportunities include deep NAV discounts, but risks involve unsustainable distributions and negative ROE/ROA. Analyst consensus is split, with 50% buy ratings reflecting divided sentiment on recovery potential versus financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
